KorngoldR, SprentJ.Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice.J Exp Med1978; 148: 1687–98.
2.
ThomasED, StorbT, CliftRABone-marrow transplantation (second of two parts).N Engl J Med1975; 292: 895–902.
3.
GoldsteinG.An overview of Orthoclone OKT3.Transplant Proc1986; 18: 927–30.
4.
PonticelliC, RivoltaE, TarantinoAClinical experience with Orthoclone OKT3 in renal transplant.Transplant Proc1986; 18: 942–8.
5.
GratamaJW, JansenJ, LipovichRA, TankeHJ, GoldsteinG, ZwaanFE. Treatment of acute graft-versus-host disease with monoclonal antibody OKT3.Transplantation1984; 38: 469–74.
6.
GluckmanE, DevergieA, VarinF, RabianC, D'AGAYMF, BenbunanM,. Treatment of steroid resistant severe acute graft versus host disease with monoclonal pan OKT3 antibody.Exp Hematol1984; 12(suppl 15): 66–7.
7.
GoldsteinG, SchindlerJ, TsaiHA randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants.N Engl J Med1985; 313: 337–42.
8.
MartinPJ, ShulmanHM, SchubachWHFatal Epstein-Barr-virus associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody.Ann Intern Med1984; 101: 310–5.
9.
Aseptic meningitis among kidney transplant recipients receiving a newly marked murine monoclonal antibody preparation.MMWR1986; 35: 551–2.
